Pharmacokinetics and pharmacodynamics of propofol in children undergoing different types of surgeries

Alicja Bartkowska-Śniatkowska1, Agnieszka Bienert2, Paweł Wiczling3

  • 1Department of Pediatric Anesthesiology and Intensive Therapy, Poznań University of Medical Sciences, Poznań, Poland.

Insights

This study quantifies the relationship between propofol concentration and Bispectral Index (BIS) in children undergoing anesthesia. Results show a strong correlation, but highlight variability requiring careful interpretation of BIS for pediatric anesthesia depth.

Area of Science:

  • Anesthesiology
  • Pharmacology
  • Pediatric Medicine

Background:

  • Propofol is a key agent for total intravenous anesthesia (TIVA).
  • Characterizing propofol's pharmacokinetics and pharmacodynamics in children is crucial but incomplete.
  • Understanding the concentration-effect relationship is vital for safe pediatric anesthesia.

Purpose of the Study:

  • To establish a quantitative link between propofol plasma concentration and Bispectral Index (BIS) in pediatric patients.
  • To characterize the pharmacodynamic response to propofol in a diverse group of children undergoing surgery.
  • To inform anesthetic management by detailing propofol's effects on EEG-derived BIS values.

Main Methods:

  • Utilized nonlinear mixed-effects modeling (NONMEM) for data analysis.
  • Collected sparse venous blood samples for propofol concentration assays.
  • Gathered dense Bispectral Index (BIS) measurements during and after propofol infusion.

Main Results:

  • A three-compartment pharmacokinetic model coupled with an Emax pharmacodynamic model, including a biophase compartment, effectively described the data.
  • Allometric scaling was applied to clearance and volume parameters based on body mass.
  • Pharmacodynamic parameters exhibited significant inter-patient variability, with a typical EC50 of 2.80 mg/L and a biophase distribution rate constant of 3.33 min⁻¹.

Conclusions:

  • Pediatric BIS values demonstrate a strong correlation with propofol effect-site concentrations via the Emax model.
  • Children exhibit slightly lower propofol sensitivity and higher clearance compared to adults.
  • Anesthesiologists must consider intra-patient BIS variability when using it as the sole indicator of anesthetic depth in pediatric patients.
Abstract

Related Concept Videos

Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
995
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
954
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
544
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
405
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
399